News
Cystic fibrosis drugs are rejected for NHS use in Scotland
BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l5137 (Published 13 August 2019) Cite this as: BMJ 2019;366:l5137- Bryan Christie
- Edinburgh
Expensive drugs to treat cystic fibrosis have been rejected for use on the NHS in Scotland, but discussions continue with the manufacturer to try to make them available.
The Scottish Medicines Consortium, which advises NHS Scotland on the use of new drugs, said that there remained “significant uncertainty” over the overall health benefits of Orkambi (combination of lumacaftor and ivacaftor) and Symkevi (tezacaftor and ivacaftor) in relation to their …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.